Jay M Moyes
CIK 1191062 · Chief Financial Officer · last filed 2026-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MYGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10880 WILSHIRE BOULEVARD, SUITE 2150
LOS ANGELES, CA 90024
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCDA | Director | — | $0.90 | — | $0 | 6 | 2026-07-07 |
| PBYI | Director | 58,322 | $10.85 | $632.8K | -$919.6K | 22 | 2026-06-15 |
| SINT | Director | 4,000 | $1.56 | $6.2K | $13.7K | 2 | 2026-02-25 |
| BioCardia, Inc. (BCDAW) Delisted | Director | 54,267 | $0.01 | $331 | $0 | 10 | 2023-10-19 |
| SERA | Chief Financial Officer | 35,630 | $2.04 | $72.7K | $0 | 3 | 2023-03-07 |
| ACHV | Director | — | $6.54 | — | $0 | 6 | 2022-06-01 |
| ACHIEVE LIFE SCIENCES, INC. (OGXI) Delisted | Director | — | — | — | $0 | 1 | 2017-08-03 |
| Sintx Technologies, Inc. (AMDA) Delisted | Chief Financial Officer | 4,438 | — | — | $0 | 1 | 2014-02-21 |
| OSIRIS THERAPEUTICS, INC. (OSIR) Delisted | Director | 26,500 | — | — | $0 | 8 | 2014-02-07 |
| MYGN | Chief Financial Officer | 52,512 | $6.02 | $316.1K | -$6.29M | 18 | 2007-10-16 |
Recent Filings · Page 5 of 9
82 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-09-26 | BCDA | Grant (A) | — | $0 | EDGAR |
| 2018-09-21 | ACHV | Grant (A) | — | $0 | EDGAR |
| 2018-06-14 | PBYI | Grant (A) | +5,822 | $0 | EDGAR |
| 2017-09-12 | ACHV | Grant (A) | — | $0 | EDGAR |
| 2017-08-25 | BCDA | Grant (A) | — | $0 | EDGAR |
| 2017-08-03 | ACHIEVE LIFE SCIENCES, INC. (OGXI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-14 | PBYI | Grant (A) | — | $0 | EDGAR |
| 2017-01-18 | BCDA | Grant (A) | — | $0 | EDGAR |
| 2016-11-16 | PBYI | Grant (A) | — | $0 | EDGAR |
| 2015-12-17 | PBYI | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.